Retatrutide
LY3437943 / Triple agonist
- Peptide length
- 39 amino acids
Acylated peptide analog
Open the sources to check how the studies were done and what they can support.
A triple receptor agonist with randomized human obesity research, including a published phase 2 trial.
- Family
- Multi-receptor incretin analog
- Research target
- GIP, GLP-1 and glucagon receptors
- Molecular form
- Acylated peptide analog
What to know about the research
Interpret weight changes with trial duration, escalation, discontinuations and comparator in view. Consult the trial register for subsequent development.
Check the exact compound
Distinguish the studied molecule from other triple agonists and from commercially described salts or research preparations.
What supports this entry?
1 of 3 summary statements linked to checked source passages.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
Check the overview statementSource checked
A triple receptor agonist with randomized human obesity research, including a published phase 2 trial.
PDF page 1: Abstract, Methods and Results
- This citation describes the 2023 phase 2 publication, not the latest development stage or a current approval determination.
Inside the selected studies
Phase 2 randomized, double-blind, placebo-controlled trial
Retatrutide (LY3437943), study formulation
- Who or what was studied
- Adults with obesity, or overweight with a weight-related condition
- Sample size
- 338
- Compared with
- Placebo
- Duration
- 48 weeks; primary body-weight endpoint at 24 weeks
- Percentage change in body weight
- Safety assessments
- This trial does not establish equivalence for another formulation or a research vial.
The remaining statements still need individual source mapping. Use the original references when checking a claim.
How we prepare and correct these entries